Evidence map›Paper›PMID 28082723›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Presenilin-1 mutations and Alzheimer's disease.

Raymond J Kelleher, Jie Shen

Abstract readComment
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed.

  1. Trial
  2. Article
  3. Aberrant phase separation from a rare ABI3 mutation drives microglial dysfunction and Alzheimer's risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Benchmarking AlphaMissense pathogenicity predictions againstBiochemistry and biophysics reports · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Raymond J KelleherDepartment of Neurology, Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Jie ShenProgram in Neuroscience, Harvard Medical School, Boston, MA 02115; jshen@rics.bwh.harvard.edu.

Funding

Role of Presenilins in the SynapseR01NS041783 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI Jie Shen · 2001 to 2026
$10.6M
PS1 &PS2 in Cortical Development and Notch SignalingR01NS042818 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SHEN, JIE · 2002 to 2017
$5.7M
Presenilin dysfunction in the brainR01NS075346 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI KELLEHER, RAYMOND J · 2011 to 2020
$4.7M
Presenilin and APP in the BrainRF1NS041783 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SHEN, JIE · 2021 to 2021
$2.7M
Research Mentoring in Neurology and Translational Research on Alzheimers DiseaseK24NS093185 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI KELLEHER, RAYMOND J · 2016 to 2020
$940k
NINDS NIH HHS K24 NS093185NINDS NIH HHS R01 NS041783NINDS NIH HHS R01 NS042818NINDS NIH HHS R01 NS075346NINDS NIH HHS RF1 NS041783
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseasePresenilin-1Amyloid beta-Protein PrecursorHumansMutationPresenilin-2Amyloid beta-Protein PrecursorPresenilin-1Presenilin-2

Identifiers

PMID28082723
PMCPMC5278466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.